Lynne Sullivan - May 11, 2023 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Role
CFO and Head of Corporate Development
Signature
/s/ Alexander Nguyen, Attorney-in-Fact for Lynne Marie Sullivan
Stock symbol
UBX
Transactions as of
May 11, 2023
Transactions value $
$110,800
Form type
4
Date filed
5/12/2023, 08:09 PM
Previous filing
Mar 3, 2023
Next filing
Jun 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UBX Stock Option (Right to Buy) Award $111K +40K $2.77 40K May 11, 2023 Common Stock 40K $2.77 Direct F1
transaction UBX Stock Option (Right to Buy) Disposed to Issuer $0 -24K -100% $0.00* 0 May 11, 2023 Common Stock 24K $99.60 Direct F2, F3
transaction UBX Stock Option (Right to Buy) Award $0 +24K $0.00 24K May 11, 2023 Common Stock 24K $2.77 Direct F2, F3
transaction UBX Stock Option (Right to Buy) Disposed to Issuer $0 -12.3K -100% $0.00* 0 May 11, 2023 Common Stock 12.3K $41.80 Direct F4, F5
transaction UBX Stock Option (Right to Buy) Award $0 +12.3K $0.00 12.3K May 11, 2023 Common Stock 12.3K $2.77 Direct F4, F5
transaction UBX Stock Option (Right to Buy) Disposed to Issuer $0 -20K -100% $0.00* 0 May 11, 2023 Common Stock 20K $10.60 Direct F6, F7
transaction UBX Stock Option (Right to Buy) Award $0 +20K $0.00 20K May 11, 2023 Common Stock 20K $2.77 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date.
F2 The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
F3 On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
F4 Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
F5 On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
F6 The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
F7 On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.

Remarks:

CFO and Head of Corporate Development